GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Operating Margin %

ZYUS Life Sciences (TSXV:ZYUS) Operating Margin % : -5,388.66% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. ZYUS Life Sciences's Operating Income for the three months ended in Dec. 2023 was C$-5.23 Mil. ZYUS Life Sciences's Revenue for the three months ended in Dec. 2023 was C$0.10 Mil. Therefore, ZYUS Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 was -5,388.66%.

The historical rank and industry rank for ZYUS Life Sciences's Operating Margin % or its related term are showing as below:

TSXV:ZYUS' s Operating Margin % Range Over the Past 10 Years
Min: -10999.52   Med: -5468.12   Max: -4313.11
Current: -4313.11


TSXV:ZYUS's Operating Margin % is ranked worse than
98.33% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 6.43 vs TSXV:ZYUS: -4313.11

ZYUS Life Sciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

ZYUS Life Sciences's Operating Income for the three months ended in Dec. 2023 was C$-5.23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was C$-15.14 Mil.


ZYUS Life Sciences Operating Margin % Historical Data

The historical data trend for ZYUS Life Sciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences Operating Margin % Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Operating Margin %
-10,999.52 -5,468.12 -4,898.01

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only -3,844.00 -3,841.03 -3,872.73 -3,973.74 -5,388.66

Competitive Comparison of ZYUS Life Sciences's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Operating Margin % falls into.



ZYUS Life Sciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ZYUS Life Sciences's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-17.192 / 0.351
=-4,898.01 %

ZYUS Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.227 / 0.097
=-5,388.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences  (TSXV:ZYUS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ZYUS Life Sciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines